Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE.
AMIKIN vs NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Polymyxin B is a cationic detergent antibiotic that disrupts bacterial cell membrane integrity by interacting with phospholipids. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
Instill 3 to 4 drops into the affected ear(s) 3 to 4 times daily. For otic suspension in adults.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Neomycin: 2-3 hours (in adults with normal renal function); may accumulate in renal impairment. Polymyxin B: 6-8 hours (prolonged in renal impairment: up to 36 hours). Hydrocortisone: 1.2-1.5 hours (terminal).
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Neomycin: >90% unchanged in feces after oral administration; negligible renal excretion. Polymyxin B: 60% renal excretion of unchanged drug; remainder nonrenal. Hydrocortisone: primarily hepatic metabolism, <5% renal excretion unchanged.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic